Search

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

Coliform Mastitis: the facts to know | Boehringer Ingelheim US

Click here to learn more about different management practices that can help you to improve your dairy herd's bottom line and productivity.

Our evolved employer value proposition

Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.

Results announced from EMPACT-MI phase III trial

Results announced from EMPACT-MI phase III trial in adults following a heart attack.

Help in all situations in life

Boehringer Ingelheim focuses on the wellbeing of its employees – and is therefore also a "Global Top Employer 2023".

Fighting Non-Communicable Diseases | Boehringer Ingelheim US

Read more on Boehringer Ingelheim's new NCD initiative, aiming to reduce NCD prevalence and capture the impact of our product portfolio for our patients.

Results from Phase II MASH trial announced at EASL 2024

Boehringer Ingelheim announced results from Phase II trial in metabolic dysfunction-associated steatohepatitis (MASH) at EASL 2024

The power of patient advocacy in cancer care

Patients and advocacy organizations agree that patient empowerment is key to quality cancer care

Welcome to the Neuroscience Gallery | Boehringer Ingelheim US

Click here to take a guided tour through our Neuroscience virtual 3-D art exhibition, helping us to improve how we diagnose and treat various diseases.

Why today’s depression trials demand smart new approaches

Saving Stroke Patients around the world

Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.

A future without pills – could AI change the way we treat psychiatric diseases?

Dr Cornelia Dorner-Ciossek talks about how her work with smartphone tech could transform how we treat mental illness.

A Holistic Approach to Cardio-Renal-Metabolic Care | Boehringer Ingelheim US

Our Blueprint for Constructing a Holistic Approach to Cardio-renal-metabolic Care

Our Environment

Expanded Access Programs

A Moment To Reflect on the Evolving Approach for Diabetes Management | Boehringer Ingelheim US

A Moment To Reflect on the Evolving Approach for Diabetes Management

Introducing Ingelvac Provenza™ | Boehringer Ingelheim US

Find out more on our new swine vaccine, offering increased protection against influenza strains affecting 70% of growing pigs annually.

Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month

Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.

Our Curiosity Never Stops | Boehringer Ingelheim US

Hear from Dr. Cornelia Dorner-Ciossek on how brain research informs treatment methods for patients suffering with mental illnesses.

Ordering your medicine online? Find a safe pharmacy first.

Learn what to look for when buying medication and how to verify your pharmacy.

What can the Patient do?

Generalized pustular psoriasis (GPP): Unmet needs, the reality of living with the condition, and future management

Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD

Sunshine Act Compliance

The Urgency for Heart Failure Research and New Treatment Options

The Central Role of Primary Care Physicians and Endocrinologists in Treating C-R-M Conditions | Boehringer Ingelheim US

The Central Role of Primary Care Physicians and Endocrinologists in Treating C-R-M Conditions

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers